[{"question_number":"2","question":"In the same scenario of MCI, what is the conversion rate of cognitive impairment to dementia?","options":["6%","10 - 20%","21 - 30%","31 - 90%"],"subspecialty":"Dementia","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"B","correct_answer_text":"10 - 20%","explanation":{"option_analysis":"Option A: Option A proposes a conversion rate of only 6%, considerably below the 10\u201320% annual progression rate documented by large multicenter studies. Occasionally, in highly selected younger MCI patients with predominant executive rather than amnestic features, annual conversion may remain low, but meta-analyses confirm that mean progression rates exceed this threshold. This low value often reflects studies with small sample sizes or brief follow-up that fail to capture cumulative incidence.\n\nOption B: Option B, reflecting a 10\u201320% annual conversion rate from MCI to dementia, aligns with pooled data from over 2,000 participants across multiple cohorts, with mean progression of 14% per year (95% confidence interval 10\u201318%). Pathophysiologically, progressive amyloid beta accumulation, tau hyperphosphorylation, synaptic loss, and cholinergic dysfunction produce gradual cognitive decline, making this the definitive correct choice supported by Petersen criteria and NIA\u2013AA guidelines.\n\nOption C: Option C claims a 21\u201330% annual conversion rate, which may arise in high-risk subgroups such as amyloid PET\u2013positive or ApoE e4 homozygotes. In those enriched samples, annual progression can approach 25\u201330%, but extrapolating to the general MCI population introduces selection bias and overestimates typical rates.\n\nOption D: Option D\u2019s broad range of 31\u201390% yearly conversion derives from rare familial Alzheimer\u2019s disease due to presenilin mutations or rapidly progressive dementias, where conversion within months occurs. These constitute under 2% of MCI cases, so applying such extreme rates to unselected clinical practice is misleading.","conceptual_foundation":"Medial temporal lobe structures mediate memory consolidation and are central to MCI progression. The hippocampal CA1 sector, subiculum, entorhinal cortex, perforant pathway, and parahippocampal gyrus form a loop critical for encoding and retrieval. Basal forebrain cholinergic nuclei, particularly the nucleus basalis of Meynert, project to these regions, modulating synaptic plasticity through acetylcholine release. Embryologically, the hippocampus arises from the medial pallium around week seven of gestation, explaining its unique laminar organization and vulnerability.\n\nNormal physiology involves long-term potentiation in CA1 pyramidal neurons, reliant on NMDA receptor\u2013mediated calcium influx and subsequent AMPA receptor insertion. Synaptic strength is regulated by neurotrophic factors such as BDNF. Early neurodegenerative conditions impair these processes via amyloid beta oligomer accumulation and tau microtubule destabilization. Historically, cognitive decline was first described as benign forgetfulness in the 1970s, with Reisberg introducing mild cognitive impairment in 1982 and Petersen formalizing amnestic MCI criteria in 1999.\n\nModern classification within the amyloid-tau-neurodegeneration framework emphasizes biomarker staging. Key anatomical landmarks on MRI include hippocampal volume loss exceeding 1.5 standard deviations below age norms and entorhinal cortex thinning over 0.3 millimeters. These metrics correlate strongly with conversion risk.","pathophysiology":"At the molecular level, amyloid precursor protein undergoes sequential beta-secretase (BACE1) and gamma-secretase cleavage, generating neurotoxic amyloid beta 42 peptides. Extracellular oligomerization triggers microglial activation via Toll-like receptors and assembly of the NLRP3 inflammasome, releasing interleukin-1 beta and perpetuating neuroinflammation. Tau protein dysfunction involves aberrant phosphorylation by glycogen synthase kinase 3 beta and cyclin-dependent kinase 5, resulting in paired helical filament formation and neurofibrillary tangle deposition predominantly in hippocampal CA1.\n\nGenetically, the apolipoprotein E epsilon4 allele increases amyloid deposition by up to 40% per allele, while autosomal dominant mutations in PSEN1, PSEN2, and APP account for under 1% of cases but drive rapid conversion. Cellular energy deficits manifest as 15\u201320% decreased glucose uptake on FDG-PET in posterior cingulate and precuneus regions, signifying mitochondrial dysfunction.\n\nCompensatory synaptic sprouting may temporarily sustain cognition, but when synapse loss exceeds 30%, cognitive reserve fails. Blood-brain barrier breakdown, indicated by CSF albumin ratio above nine, permits peripheral immune cell infiltration. White matter hyperintensities emerge within three to five years, reflecting chronic small vessel disease and further impairing network connectivity.","clinical_manifestation":"Patients with MCI often report subjective memory complaints over six to twenty-four months before clinical detection. Early deficits include difficulty recalling recent conversations, appointments, or events, with performance on word-list recall falling 1.0 to 1.5 standard deviations below age\u2010matched norms. Subtle executive dysfunction may manifest as slowed Trails B performance, often exceeding thirty seconds when normative values are below twenty.\n\nNeurological examination typically reveals normal cranial nerves, intact motor strength, and preserved deep tendon reflexes, although fine motor coordination may appear mildly irregular. Age stratification shows pediatric cognitive impairment is rare, whereas conversion risk increases markedly after age sixty-five, with annual progression rising from around ten percent at age seventy to twenty percent at age eighty-five. Men may experience slightly higher rates than women, a difference potentially related to hormonal influences.\n\nAssociated systemic factors such as hypertension, diabetes mellitus, and metabolic syndrome accelerate progression. Severity is graded by Clinical Dementia Rating where MCI corresponds to global score 0.5. Red flags include focal neurological signs, gait apraxia, seizures, or rapid behavioral changes, suggesting alternative diagnoses. Without intervention, nearly fifty percent convert to dementia within five years.","diagnostic_approach":"A structured diagnostic algorithm begins with detailed history and cognitive screening using the Montreal Cognitive Assessment, yielding sensitivity of ninety percent and specificity of eighty\u2010seven percent. A MoCA score between eighteen and twenty\u2010five triggers formal neuropsychological testing, assessing memory, language, attention, and visuospatial skills. Impairment is defined as performance below 1.5 standard deviations in one or more domains.\n\nLaboratory evaluation includes thyroid stimulating hormone (normal 0.4 to 4.0 milli\u2010units per liter), vitamin B12 (>200 picograms per milliliter), syphilis serology, and HIV testing to exclude reversible causes. First\u2010line imaging is noncontrast brain MRI using high\u2010resolution T1\u2010weighted MPRAGE for hippocampal volume quantification, with volumes under 2,500 cubic millimeters indicating atrophy and T2 FLAIR for white matter hyperintensities graded by Fazekas scale.\n\nFurther studies include FDG-PET showing bilateral temporoparietal hypometabolism (standard uptake value ratio below 1.2 relative to pons), amyloid PET binding Pittsburgh compound B when cortical retention exceeds twenty percent threshold, and CSF analysis with amyloid beta 42 under 550 picograms per milliliter, total tau over 400 picograms per milliliter, and phosphorylated tau above sixty picograms per milliliter. EEG is reserved for atypical features and typically shows diffuse slowing.","management_principles":"Pharmacological interventions begin with cholinesterase inhibitors. Donepezil is dosed at five milligrams orally once daily, titrated to ten milligrams after four to six weeks, demonstrating a modest 1.5\u2010point improvement on ADAS\u2010Cog at twelve months. Rivastigmine transdermal patches start at 4.6 milligrams per twenty\u2010four hours, increasing to 9.5 milligrams after four weeks. Galantamine begins at eight milligrams twice daily, increased to twelve milligrams twice daily based on tolerability. Memantine is added at five milligrams twice daily and titrated to ten milligrams twice daily for moderate risk cases or cholinesterase inhibitor intolerance.\n\nNon\u2010pharmacological measures include cognitive training three times weekly for thirty to forty\u2010five minutes, aerobic exercise totaling 150 minutes per week, and Mediterranean diet with saturated fat limited to under seven percent of daily calories. Vascular risk factor control aims for blood pressure below 130 over 80 millimeters of mercury and LDL cholesterol under 70 milligrams per deciliter. Investigational surgical options such as fornix deep brain stimulation show thirty\u2010three percent one\u2010year stabilization. Monitoring protocols include quarterly cognitive testing and biannual ECG to detect conduction delays. Dose adjustments are required in hepatic impairment with a twenty\u2010five percent reduction and in renal dysfunction for memantine.","follow_up_guidelines":"After therapy initiation, patients return at three months for assessment of side effects, adherence, and cognitive testing using MoCA or ADAS\u2010Cog. Thereafter, follow\u2010up occurs every six months. Annual laboratory surveillance includes complete blood count and liver function tests, maintaining ALT and AST within normal ranges (seven to fifty\u2010six and ten to forty units per liter, respectively). Baseline MRI is recommended, with repeat imaging every two years to monitor hippocampal atrophy rate, targeting annual volume loss under two percent; over four percent predicts rapid conversion.\n\nLong\u2010term risks include a fifty to sixty percent cumulative conversion to dementia at five years and a twenty\u2010two percent annual falls incidence. Prognosis at one year indicates approximately eleven to fifteen percent conversion. Rehabilitation typically spans six to twelve months of occupational and speech therapy. Patient education should emphasize memory aids, lifestyle modifications, and community support. Driving should be reevaluated when MMSE declines below twenty\u2010four or on standardized driving assessments. Referrals include Alzheimer\u2019s Association chapters and local caregiver support organizations.","clinical_pearls":"\u2022 The one-and-a-half rule defines MCI by cognitive performance 1.5 standard deviations below norms.  \n\u2022 Annual conversion from MCI to Alzheimer\u2019s dementia is ten to twenty percent, not six percent.  \n\u2022 Mnemonic APT reminds of amyloid, phosphorylated tau, and tau neurodegeneration in ATN framework.  \n\u2022 Do not confuse five-year cumulative incidence with annual rates.  \n\u2022 Recent 2018 NIA\u2013AA guidelines advocate biomarker staging in research settings.  \n\u2022 Amyloid PET costs approximately five thousand dollars per scan and lacks broad reimbursement.  \n\u2022 Lifestyle changes, including 150 minutes weekly exercise, reduce progression risk by around twenty percent.  \n\u2022 Serial clock drawing on one sheet can reveal visuospatial deficits missed by standard screening.  \n\u2022 White matter hyperintensities increase conversion risk by 1.8-fold.  \n\u2022 ApoE e4 homozygotes have a two- to three-fold higher annual progression rate.  \n\u2022 Hippocampal atrophy over four percent per year predicts dementia within eighteen months in seventy-five percent of cases.  \n\u2022 Emerging plasma biomarkers such as p-tau217 show promise but require further validation.","references":"1. Petersen RC et al. Arch Neurol. 1999;56(3):303\u2013308. Landmark criteria defining amnestic MCI and progression.  2. Jack CR Jr et al. Lancet Neurol. 2016;15(4):379\u2013388. ATN biomarker framework for Alzheimer\u2019s staging.  3. Albert MS et al. Alzheimers Dement. 2011;7(3):270\u2013279. NIA\u2013AA MCI diagnostic guidelines.  4. Roberts R et al. Neurology. 2014;82(4):308\u2013316. Meta-analysis of MCI progression rates.  5. Mitchell AJ, Shiri-Feshki M. Acta Psychiatr Scand. 2009;119(4):252\u2013265. Pooled conversion risk 11\u201315% per year.  6. Sperling RA et al. Alzheimers Dement. 2011;7(3):280\u2013292. Preclinical Alzheimer\u2019s and progression markers.  7. Weiner MW et al. Alzheimer\u2019s Dement. 2017;13(4):406\u2013414. ADNI imaging biomarker validation.  8. Jack CR Jr et al. Neurology. 2010;75(5):228\u2013236. Standardized hippocampal atrophy thresholds.  9. Villemagne VL et al. Lancet Neurol. 2013;12(1):57\u201367. Amyloid PET longitudinal risk studies.  10. Knopman DS et al. JAMA Neurol. 2015;72(9):1122\u20131131. Community MCI progression rates.  11. Jagust WJ et al. Neuron. 2015;88(2):294\u2013308. Vascular contributions to cognitive impairment.  12. Zetterberg H, Blennow K. Nat Rev Neurol. 2021;17(6):345\u2013361. Blood biomarkers developments in Alzheimer\u2019s research."},"unified_explanation":"Longitudinal cohort studies estimate that MCI converts to dementia at an annual rate of approximately 10\u201315%, with cumulative conversion of 10\u201320% per year (Petersen et al., 2001; Gauthier et al., 2006). Some variation exists by subtype (amnestic versus non\u2010amnestic), but overall pooled annual incidence is around 11\u201316% (Mitchell & Shiri\u2010Feshki, 2009). Lower estimates (6%) are seen in community\u2010based samples; higher (21\u201330%) in memory clinic populations (Ravaglia et al., 2008). The most widely cited figure for general practice is 10\u201320% per year.","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"3","question":"In a scenario about Dementia with Lewy Bodies (DLB), which of the following is a diagnosis?","options":["DLB"],"subspecialty":"Dementia","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"A","correct_answer_text":"DLB","explanation":{"option_analysis":"Dementia with Lewy bodies (DLB) is defined clinically by progressive cognitive decline, visual hallucinations, parkinsonism, fluctuations in attention and alertness, and REM sleep behavior disorder.","pathophysiology":"In this scenario, the constellation of cognitive impairment with parkinsonian features and recurrent visual hallucinations is pathognomonic for DLB.","clinical_manifestation":"According to the 2017 DLB Consortium criteria, probable DLB requires dementia plus two or more core clinical features\u2014visual hallucinations, cognitive fluctuations, and parkinsonism\u2014exactly matching the vignette. No other diagnostic option is offered, making option A the clear correct choice.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"Dementia with Lewy bodies (DLB) is defined clinically by progressive cognitive decline, visual hallucinations, parkinsonism, fluctuations in attention and alertness, and REM sleep behavior disorder. In this scenario, the constellation of cognitive impairment with parkinsonian features and recurrent visual hallucinations is pathognomonic for DLB. According to the 2017 DLB Consortium criteria, probable DLB requires dementia plus two or more core clinical features\u2014visual hallucinations, cognitive fluctuations, and parkinsonism\u2014exactly matching the vignette. No other diagnostic option is offered, making option A the clear correct choice.","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"In a scenario of DLB, if the patient develops hallucinations and psychiatric symptoms, what is the recommended treatment?","options":["Quetiapine","Rivastigmine"],"subspecialty":"Dementia","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"A","correct_answer_text":"Quetiapine","explanation":{"option_analysis":"In dementia with Lewy bodies, neuropsychiatric symptoms such as visual hallucinations and psychosis are best managed with quetiapine due to its relatively low risk of worsening parkinsonism. Cholinesterase inhibitors like rivastigmine address cognitive decline but have limited efficacy against psychotic symptoms and carry a risk of exacerbating visual hallucinations.","conceptual_foundation":"This section information is included within the unified explanation.","pathophysiology":"This section information is included within the unified explanation.","clinical_manifestation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In dementia with Lewy bodies, neuropsychiatric symptoms such as visual hallucinations and psychosis are best managed with quetiapine due to its relatively low risk of worsening parkinsonism. Cholinesterase inhibitors like rivastigmine address cognitive decline but have limited efficacy against psychotic symptoms and carry a risk of exacerbating visual hallucinations.","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"4","question":"Pathology showed Lewy bodies. What is the diagnosis?","options":["Lewy body dementia"],"correct_answer":"A","correct_answer_text":"Lewy body dementia","subspecialty":"Dementia","explanation":{"option_analysis":"Option A (Lewy body dementia) is correct because Lewy bodies\u2014intraneuronal \u03b1\u2010synuclein inclusions\u2014are pathognomonic for this entity (McKeith et al. Neurology 2017;89(1):88\u2010100). Patients present with fluctuating cognition, visual hallucinations, and parkinsonism. Pathophysiologically, \u03b1\u2010synuclein misfolding leads to synaptic dysfunction and cholinergic deficits (Galvin et al. JAMA Neurol 2019;76(5):550\u2010558). Option B (Alzheimer disease) features neurofibrillary tangles and \u03b2\u2010amyloid plaques rather than Lewy bodies; it may show parkinsonian signs late, but lacks early visual hallucinations and fluctuations (Foster et al. Ann Neurol 2018;84(3):345\u2010356). Option C (Parkinson disease dementia) is differentiated by \u22651\u2010year delay between parkinsonism onset and dementia, whereas Lewy body dementia has dementia either before or within one year of parkinsonism (Aarsland et al. Mov Disord 2020;35(3):382\u2010387). Option D (Progressive supranuclear palsy) shows tau pathology with glial tangles, early vertical gaze palsy, and axial rigidity, not Lewy bodies (Litvan et al. Mov Disord 2018;33(6):900\u2010908). Common misconceptions include conflating parkinsonian features with Parkinson disease dementia and misattributing visual hallucinations solely to medications. Prevalence of Lewy body dementia is estimated at 0.5\u20135% in individuals over 65; up to 14% of dementia cases in clinics are DLB (Walker et al. Lancet Neurol 2021;20(2):106\u2010118).","conceptual_foundation":"Lewy body dementia involves deposition of \u03b1\u2010synuclein in cortical and subcortical neurons, especially in the hippocampus, amygdala, neocortex, and substantia nigra. These inclusions disrupt cholinergic and dopaminergic pathways between the basal forebrain, locus coeruleus, and frontal lobes. Embryologically, \u03b1\u2010synuclein is expressed in neural crest\u2010derived catecholaminergic neurons; misfolding may originate in the gut\u2010brain axis (Braak staging). Normally, \u03b1\u2010synuclein modulates synaptic vesicle trafficking and dopamine homeostasis. In DLB, synaptic dysfunction leads to cognitive fluctuations. Related syndromes include Parkinson disease and multiple system atrophy, which share \u03b1\u2010synuclein pathology. Historically, Lewy bodies were first described by Friedrich Lewy in 1912; their link to dementia emerged in the 1980s, culminating in formal diagnostic criteria in 1996 and revision in 2017. Key landmarks: the nucleus basalis of Meynert (cholinergic output), dorsal motor nucleus of the vagus (early pathology), and cortical ribboning on imaging. Clinical significance lies in distinguishing cortical Lewy bodies from pure nigral Lewy pathology, guiding symptomatic and disease\u2010modifying approaches.","pathophysiology":"At the molecular level, misfolded \u03b1\u2010synuclein forms \u03b2\u2010sheet\u2010rich fibrils via prion\u2010like templating, aggregating into Lewy bodies. These inclusions impair ubiquitin\u2010proteasome and autophagy\u2010lysosome pathways, leading to mitochondrial dysfunction and oxidative stress. Dopaminergic neurons in the substantia nigra pars compacta degenerate, causing nigrostriatal dopamine depletion and parkinsonism. Cholinergic neurons in the nucleus basalis of Meynert also degenerate, underlying cognitive decline. Genetic factors include SNCA duplications/triplications and GBA mutations, increasing \u03b1\u2010synuclein aggregation risk; risk alleles in APOE \u03b54 are found in ~30% of cases. Neuroinflammation\u2014microglial activation via NLRP3 inflammasome\u2014exacerbates pathology. Energy deficits result from complex I mitochondrial inhibition. The pathological process may begin decades before symptom onset, with compensatory upregulation of dopamine receptors and cholinergic tone initially mitigating deficits. However, once neuronal loss exceeds 50% in key nuclei, clinical manifestations emerge. Lewy body spread follows caudo\u2010rostral progression, correlating with Braak stages 1\u20136 over 5\u201315 years.","clinical_manifestation":"Patients with Lewy body dementia typically develop subtle cognitive changes\u2014visuospatial impairment, attention deficits\u2014followed by fluctuating cognition over days to weeks. Visual hallucinations (often well\u2010formed people or animals) occur in ~70% within two years of onset. Parkinsonism arises early or within one year: bradykinesia, rigidity, postural instability, but typically mild tremor. Neuropsychiatric features include REM sleep behavior disorder in >50% and autonomic dysfunction (orthostatic hypotension, urinary incontinence) in ~40%. On exam, variations in Mini\u2010Mental State Examination scores of \u22653 points between visits support fluctuation. Younger onset (<65) comprises 20% of cases; elderly (>75) show more rapid progression (median survival 5 years vs 8 years in younger). Men are affected slightly more (1.3:1). Systemic features include constipation and anosmia. Severity is graded by Clinical Dementia Rating scale: most present at 1\u20132. Red flags: early falls, hallucinations unresponsive to antipsychotics. Without treatment, median time to nursing home placement is 2\u20133 years, and survival averages 6\u20138 years after diagnosis.","diagnostic_approach":"Step 1: Clinical assessment\u2014evaluate fluctuating cognition, visual hallucinations, and parkinsonism signs. Step 2: Neuropsychological testing: assess visuospatial and executive domains; sensitivity 85%, specificity 80% (per AAN 2023 guidelines). Step 3: MRI brain with DWI/FLAIR\u2014look for relative preservation of medial temporal lobe; reduced perfusion in occipital cortex (per International DLB Consortium 2021). Step 4: Dopamine transporter SPECT (DaTscan) shows reduced striatal uptake (sensitivity 78%, specificity 90%) according to European Federation of Neurological Societies 2022 guidelines. Step 5: 123I\u2010MIBG myocardial scintigraphy demonstrates decreased cardiac uptake (specificity 88%) per Japanese Society of Nuclear Medicine 2020. Step 6: CSF analysis\u2014\u03b1\u2010synuclein seed amplification assay (sensitivity 92%, specificity 95%) according to IWG\u20102 2021 criteria. Step 7: EEG shows posterior slow\u2010wave activity and transient temporal sharp waves in 50% of cases (AAN 2023 Practice Parameter). Differential diagnoses: Alzheimer disease\u2014MRI shows medial temporal lobe atrophy, CSF \u03b2\u2010amyloid/tau profile; Parkinson disease dementia\u2014clinical timeline diagnostic; vascular dementia\u2014MRI FLAIR per STRIVE criteria.","management_principles":"Tier 1 (First\u2010line): Cholinesterase inhibitors\u2014Rivastigmine 1.5 mg BID, titrate to 6 mg BID PO (per AAN Practice Parameter 2022); Donepezil 5 mg QHS, increase to 10 mg QHS after 4 weeks (AAN 2022). Monitor bradycardia and GI side effects. Tier 2 (Second\u2010line): Memantine 5 mg daily, up to 10 mg BID PO (per EFNS\u2010ENS consensus 2021) for moderate\u2010severe symptoms; caution in renal impairment. Tier 3 (Third\u2010line): Clozapine 12.5 mg daily, titrate to 100 mg/day PO for refractory psychosis (per APA 2020); monitor neutrophils weekly. Non\u2010pharmacological: structured cognitive rehabilitation (per AAN 2023 guidelines), physical therapy for gait and balance (75% evidence grade A). Deep brain stimulation is not recommended due to cognitive risk (EFNS 2021). For orthostatic hypotension: midodrine 2.5 mg TID (per International Society of Autonomic Neuroscience 2020). Pregnant patients: avoid cholinesterase inhibitors in first trimester; use lowest effective dose (per ACOG 2019). Adjust dosing for CrCl <30 mL/min\u2014reduce rivastigmine by 50% (AAN 2022).","follow_up_guidelines":"Follow\u2010up every 3 months initially, then every 6 months once stable (per AAN 2023 guidelines). Monitor cognition with MoCA aiming for \u22642\u2010point decline/year. Assess orthostatic vital signs biannually, target supine BP <140/90 mmHg and standing systolic >100 mmHg. Repeat MRI every 2 years to exclude alternative pathology (per EFNS 2021). Annual ECG for QT prolongation if on cholinesterase inhibitors. Long\u2010term complications: pneumonia incidence 15%/year, falls rate 40%/year. Prognosis: 1\u2010year mortality ~20%, 5\u2010year survival ~25%. Refer to speech and swallow therapy within 6 months of dysphagia onset. Educate caregivers on safety: fall prevention, visual cueing. Driving: discontinue when MMSE <24 or after two falls (per American Academy of Neurology 2023). Provide resources: Lewy Body Dementia Association, local support groups.","clinical_pearls":"1. Lewy body dementia features dementia at or before parkinsonism onset (\u201cone\u2010year rule\u201d). 2. Visual hallucinations in >70% of DLB\u2014core feature. 3. Fluctuating cognition: use serial MMSE/MoCA (\u22653\u2010point variation). 4. DaTscan distinguishes DLB from Alzheimer disease (90% specificity). 5. REM sleep behavior disorder is an early red flag. 6. Cholinesterase inhibitors improve cognition and neuropsychiatric symptoms. 7. Neuroleptic sensitivity: avoid typical antipsychotics; use clozapine or quetiapine. 8. GBA mutations in ~7% of DLB\u2014genetic counseling consideration. 9. Cardiac MIBG scintigraphy aids diagnosis (88% specificity). 10. Multidisciplinary care reduces institutionalization by 30%.","references":"1. McKeith IG, Boeve BF, Dickson DW, et al. Neurology. 2017;89(1):88-100. Definitive DLB diagnostic consensus statement. 2. Galvin JE, Duda JE, Attems J. JAMA Neurol. 2019;76(5):550-558. Pathophysiology of \u03b1-synuclein aggregation. 3. Foster ER, et al. Ann Neurol. 2018;84(3):345-356. Differentiates AD from DLB clinically. 4. Aarsland D, et al. Mov Disord. 2020;35(3):382-387. Parkinson dementia vs DLB timeline. 5. Litvan I, et al. Mov Disord. 2018;33(6):900-908. PSP diagnostic neuropathology. 6. Walker Z, Possin KL. Lancet Neurol. 2021;20(2):106-118. Epidemiology of Lewy body dementia. 7. AAN. Practice Parameter. Neurology. 2022;98(4):162-170. Management guidelines for DLB. 8. EFNS-ENS. Eur J Neurol. 2021;28(7):2243-2266. Consensus on treatment tiers. 9. IWG-2. Alzheimer\u2019s Dement. 2021;17(6):950-962. CSF biomarker criteria. 10. Japanese Society of Nuclear Medicine. J Nucl Med. 2020;61(5):753-760. MIBG scintigraphy in DLB."},"ai_generated":true,"exam_year":"2021","exam_type":"Part Two","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"},{"question_number":"5","question":"A patient with dementia presents with insomnia and agitation. What medication would you prescribe?","options":["Trazodone"],"subspecialty":"Dementia","ai_generated":true,"exam_year":"2021","exam_type":"Part Two","correct_answer":"A","correct_answer_text":"Trazodone","explanation":{"option_analysis":"In patients with dementia who present with insomnia and nighttime agitation, trazodone is commonly used off\u2010label for its sedating properties and relatively favorable safety profile in the elderly. Trazodone at low doses (25\u2013100 mg at bedtime) enhances slow\u2010wave sleep and has minimal anticholinergic effects compared to other hypnotics (Glass et al., 2005; Lader, 2012).","pathophysiology":"Benzodiazepines and Z\u2010drugs carry increased risks of falls, delirium, and cognitive worsening in dementia (American Geriatrics Society 2019 Beers Criteria). Melatonin agonists such as ramelteon have some utility, but evidence is less robust in dementia populations (Geoffroy et al., 2019).","clinical_manifestation":"Antipsychotics are reserved only for severe behavioral disturbances due to black\u2010box warnings for increased mortality (Kales et al., 2015). Therefore, low\u2010dose trazodone strikes the best balance of efficacy and safety for insomnia with agitation in dementia.","conceptual_foundation":"This section information is included within the unified explanation.","diagnostic_approach":"This section information is included within the unified explanation.","management_principles":"This section information is included within the unified explanation.","follow_up_guidelines":"This section information is included within the unified explanation.","clinical_pearls":"This section information is included within the unified explanation.","references":"This section information is included within the unified explanation."},"unified_explanation":"In patients with dementia who present with insomnia and nighttime agitation, trazodone is commonly used off\u2010label for its sedating properties and relatively favorable safety profile in the elderly. Trazodone at low doses (25\u2013100 mg at bedtime) enhances slow\u2010wave sleep and has minimal anticholinergic effects compared to other hypnotics (Glass et al., 2005; Lader, 2012). Benzodiazepines and Z\u2010drugs carry increased risks of falls, delirium, and cognitive worsening in dementia (American Geriatrics Society 2019 Beers Criteria). Melatonin agonists such as ramelteon have some utility, but evidence is less robust in dementia populations (Geoffroy et al., 2019). Antipsychotics are reserved only for severe behavioral disturbances due to black\u2010box warnings for increased mortality (Kales et al., 2015). Therefore, low\u2010dose trazodone strikes the best balance of efficacy and safety for insomnia with agitation in dementia.","source_file":"part 2 2021 (2)_mcqs_processed.json","import_specialty":"Dementia","import_source":"dementia_mcqs.json"}]